Synedgen, Inc. - Award Notice
Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEBARDA - ASPR / DAAPPO / BARDA DCMAWASHINGTON, DC, 20515, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT (AN13)

Original Source

https://sam.gov/opp/c1ffcbe16ca34b3b84442b75316d1210/view
Timeline
    Description

    The Department of Health and Human Services (HHS) has awarded a federal contract to Synedgen, Inc. for the advance development of PAAG17G (DP), a high molecular weight glycopolymer designed as a medical countermeasure to mitigate mortality and morbidity following exposure to lethal ionizing radiation. This contract, valued at $16,937,463, emphasizes the government's commitment to enhancing public health safety in emergency situations, particularly in the context of biodefense and medical innovation. The project will be performed in Claremont, California, with the contract effective from September 26, 2024, and responses to the associated solicitation number BAA-23-100-SOL-00004 due by October 2, 2024. For further inquiries, interested parties may contact Jonathan Gonzalez, the Contracting Officer, at Jonathan.Gonzalez@hhs.gov or (202) 381-7248.

    Point(s) of Contact
    Jonathan Gonzalez, Contracting Officer
    (202) 381-7248
    Jonathan.Gonzalez@hhs.gov
    Joann Kambaja, Contract Specialist
    (202) 913-5470
    Joann.Kambaja@hhs.gov
    Files
    Title
    Posted
    SAM Post Award Notification - 9.26.2024 (Synedgen).pdf
    The awarded contract number 75A50124C00047, effective from September 26, 2024, pertains to the advance development of PAAG17G (DP:MIIST305), a high molecular weight glycopolymer intended as a medical countermeasure against lethal ionizing radiation. The contract, valued at $16,937,463, was awarded to Synedgen, Inc. It falls under PSC 6505 and will be performed in the United States. The solicitation number associated with the award is BAA-23-100-SOL-00004, and responses are due by October 2, 2024. The contracting officer managing this procurement is Jonathan Gonzalez from the Department of Health and Human Services (HHS). The project focuses on developing a daily oral treatment designed to minimize mortality and morbidity resulting from radiation exposure, which underscores the government's emphasis on enhancing public health safety in emergency situations. This contract represents a strategic investment in biodefense and medical innovation to address potential radiological threats.
    Lifecycle
    Title
    Type
    Synedgen, Inc. - Award Notice
    Currently viewing
    Special Notice
    Similar Opportunities
    Radiation Dosimetry
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Biomedical Advanced Research and Development Authority (BARDA), is seeking proposals for the development of standardized radiation dosimetry guidelines for nonclinical models used in radiation research. The primary objective is to create harmonized dosimetry practices across BARDA's research portfolio, which is crucial for ensuring consistent and comparable data in medical countermeasures against various threats, including chemical, biological, radiological, and nuclear hazards. This five-year contract includes a two-year base period with three optional one-year extensions, and it requires comprehensive services such as irradiator assessments and the fabrication of phantoms for animal models. Interested vendors should submit their proposals, including detailed organizational information and past performance documentation, by the specified deadlines, with the estimated award date projected for the third quarter of fiscal year 2025. For further inquiries, contact Audrey Glover at audrey.glover@hhs.gov or Joann Kambaja at Joann.Kambaja@hhs.gov.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) aimed at addressing public health threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, as well as emerging infectious diseases and pandemic influenza. The initiative seeks to foster public-private partnerships to enhance the development and responsiveness of life-saving MCMs, emphasizing the importance of technological maturity, regulatory compliance, and manufacturing standards in the evaluation process. This opportunity is critical for strengthening national health security and improving preparedness for future public health emergencies, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties can direct inquiries to BARDA-BAA@hhs.gov for further information.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases and enhancing biodefense capabilities. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 are due by January 21, 2025. Interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to enhance public health preparedness against various threats, including infectious diseases and chemical agents. The initiative invites submissions across multiple Areas of Interest (AOIs), including but not limited to vaccine innovations, diagnostic technologies, and therapeutic solutions for acute radiation syndrome and chemical threats. This opportunity is critical for advancing biomedical research and developing effective responses to health emergencies, with multiple awards anticipated based on scientific merit and funding availability. Interested parties must register on SAM.gov and submit their abstracts by specified deadlines, with key submission dates ranging from March 15, 2024, to May 31, 2024, depending on the AOI. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Award Notice
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), has announced the FY24 Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. This opportunity aims to support innovative research projects that enhance regulatory science, with a focus on health, medical, and biotechnology advancements. The awarded contracts, totaling over $24 million, cover a range of critical topics including drug safety, gene therapy, and methodologies for assessing pediatric opioid exposure, reflecting the federal government's commitment to fostering research initiatives that improve healthcare delivery and regulatory processes. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Brand Name Biological Product
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for a brand name biological product under solicitation number RFQ-NIAID-25-2251721. The procurement involves the acquisition of specific biological supplies, including various anti-human antibodies, to support the National Institute of Allergy and Infectious Diseases (NIAID) in its research efforts. These products are critical for advancing biomedical research and ensuring the availability of high-quality reagents for scientific studies. Interested vendors must submit their offers by December 22, 2024, at 10:00 AM EST, and can direct inquiries to Calvin Robinson at calvin.robinson@nih.gov.
    Public Health Industrial Base Capabilities and Capacities: Anti-Microbials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking industry partners to provide information regarding domestic production capabilities related to anti-microbials under the Defense Production Act Title III Program. The objective of this Request for Information (RFI) is to identify gaps in the Public Health Industrial Base (PHIB) and enhance national defense resources by focusing on the production of essential medicines and medical countermeasures sourced domestically. Respondents are encouraged to share insights on their manufacturing processes, regulatory compliance, and infrastructure, as well as past supply chain disruptions and investment needs, with responses due by January 6, 2025, at 10 AM ET. Interested parties should submit their responses to Chris Newell at IBMSC-Submissions@hhs.gov.
    FY25 Bulk Pharma Buy (Materiel)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from vendors regarding the procurement of pharmaceuticals for the Strategic National Stockpile (SNS) under the FY25 Bulk Pharma Buy initiative. The primary objective is to identify suppliers capable of providing FDA-approved medications, including Amoxicillin, Ciprofloxacin, and Clindamycin, in specified formulations and quantities, as detailed in the associated RFI documents. This procurement is crucial for ensuring rapid access to essential medical supplies during public health emergencies, such as biological or chemical threats and natural disasters. Interested vendors must submit their capabilities and relevant information electronically by January 9, 2025, to Terri Reed at terri.reed@hhs.gov, with the understanding that responses will not be returned and will be treated as public knowledge.
    BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT IN SUPPORT OF THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND), JPM MEDICAL AND JPL EB
    Active
    Dept Of Defense
    Solicitation DEPT OF DEFENSE is seeking research and development services in support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB. The service being procured is for the identification of the best available science in the areas of research interest, including novel solutions and improved methods for developing medical countermeasures. The government is specifically interested in enabling technologies, life cycle bioinformatics, and improved logistics tracking. The procurement notice is available on SAM.gov and the JPEO-CBD website. Potential offerors are encouraged to communicate with the JPMO technical contacts for proposal ideas. For any questions or inquiries, contact usarmy.detrick.mcs.mbx.baa@mail.mil.
    Potassium Iodide
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of the Assistant Secretary for Administration, is seeking qualified vendors to supply Potassium Iodide (KI) tablets, specifically the Thyrosafe brand or an equivalent, in blister packs of 20 tablets. The procurement requires a total quantity of 224,601 packages, each containing 20 tablets of 65mg KI, which is critical for public health preparedness in the event of nuclear emergencies. Interested small businesses are encouraged to participate, as this opportunity is set aside for total small business participation under FAR 19.5. For further details, vendors may contact Tim Bouchelle at Timothy.Bouchelle@hhs.gov or by phone at 443-947-6039.